1. Introduction {#sec1-ijerph-17-05171}
===============

Six months after the first case of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reported in Wuhan, China, in December 2019, the virus has spread worldwide \[[@B1-ijerph-17-05171],[@B2-ijerph-17-05171]\]. The World Health Organization has declared that the ongoing pandemic of coronavirus disease 2019 (COVID-19) represents a public health emergency of international concern. Even though governments all around the world have adopted control measures, mainly through social distancing and isolation of patients, the coronavirus outbreak has affected over 200 countries with approximately 8 million confirmed cases and over 445,000 deaths worldwide as of 1 June 2020 \[[@B3-ijerph-17-05171]\]. Spain was the second country in Europe after Italy to suffer the COVID-19 pandemic, with the first case reported in January 2020, and is one of the countries with the highest number of attributable deaths after the United Kingdom, Italy and France at the moment of writing this study \[[@B3-ijerph-17-05171]\].

The impact of the disease has varied among countries, sub-populations and ethnicities in terms of fatality rates and other health-related outcomes, which could be explained not only by genetic differences but also by diverse cultural, political, and socio-behavioral factors \[[@B4-ijerph-17-05171],[@B5-ijerph-17-05171]\]. Its rapid geographic spread across countries requires large-scale epidemiological studies to ascertain and develop effective health policies considering the general context in which the outbreak has taken place.

The first published reports of COVID-19 were mostly case series of hospitalized patients, describing the more severe end of the clinical spectrum of the disease \[[@B6-ijerph-17-05171]\], mainly life-threatening pneumonia. Later observational studies reported a wide range of symptoms, from asymptomatic infection to respiratory failure and death \[[@B7-ijerph-17-05171]\]. It has been estimated that eight out of every ten patients infected with SARS-CoV-2 will develop mild symptoms, while the remaining two can evolve to severe or critical conditions \[[@B8-ijerph-17-05171]\].

As with other acute respiratory infections, certain comorbidity profiles could predispose COVID-19 patients to more frequent adverse outcomes. Several chronic conditions, such as diabetes, hypertension, cardiovascular disease, cerebrovascular disease, or chronic obstructive pulmonary disease have already been identified \[[@B9-ijerph-17-05171],[@B10-ijerph-17-05171]\], while other factors, such as older age or d-dimer levels on admission over 1 μg/mL in hospitalized patients, have also been found to entail poorer health outcomes \[[@B8-ijerph-17-05171],[@B11-ijerph-17-05171]\]. However, previous reports on the role that other baseline chronic conditions and medications play in the evolution and outcomes of infected patients are contradictory, and the relevance of these factors remains unclear.

Longitudinal, population-based epidemiological studies, in both inpatient and outpatient settings, including baseline information on every possible disease and medication, are necessary to shed light on the risk factors behind the most severe cases. The results of such an approach are relevant for the early identification of patients susceptible to poorer health outcomes and, therefore, potential targets of specific prevention strategies and/or of closer clinical monitoring.

This exploratory study aims to analyze which socio-demographic and clinical factors are associated with an increased risk of mortality in a Spanish cohort of individuals infected by COVID-19, with a particular focus on baseline chronic diseases and treatments present at the time of infection.

2. Materials and Methods {#sec2-ijerph-17-05171}
========================

2.1. Design and Study Population {#sec2dot1-ijerph-17-05171}
--------------------------------

We conducted a retrospective cohort study (PRECOVID Study), including all individuals with laboratory-confirmed infection by SARS-CoV-2 in the Spanish region of Aragon (reference population, 1.3 million inhabitants), from a total of 14,724 laboratory-tested individuals. In Aragon, the national health system provides free-of-charge healthcare with universal coverage to approximately 95% of the population. The PRECOVID Study was created to serve as the basis for future observational studies on the epidemiology and trajectory of the disease through the linkage of real-world data from patients' electronic health records (EHRs) and clinical-administrative databases.

For this study, we included all the individuals of the cohort from 4 March 2020 (i.e., date of the first confirmed infection in the region) to 17 April 2020 (enrolment period). We followed patients from the date of inclusion in the cohort to 17 May 2020, or to the date of death, to ensure a minimum follow-up period of 30 days for all analyzed patients and allow sufficient time for the studied event (i.e., death) to occur. Laboratory tests were conducted in the region to confirm the infection in hospitalized patients with compatible symptoms, exposed healthcare workers, residents and workers from social care institutions where an outbreak was taking place (e.g., residential homes for the elderly; physical or mental disability care centers), and individuals at a community level associated to family or work-related clusters of cases.

This study was conducted in line with the Declaration of Helsinki, as revised in 2013. The Clinical Research Ethics Committee of Aragón (CEICA) approved the research protocol (PI20/226). CEICA waived the requirement to obtain informed consent from patients given the epidemiological nature of the project, which used anonymized data.

2.2. Variables of Study and Data Sources {#sec2dot2-ijerph-17-05171}
----------------------------------------

For each individual of the cohort, we analyzed the following baseline variables at the time of inclusion: (i) socio-demographic characteristics: Sex, age (0--14, 15--44, 45--64, 65--79, ≥80 years), country of birth (native vs. non-native), administrative health area (urban vs. rural), and deprivation index of the area measured at an aggregated level and divided into four quartiles from least (Q1) to most (Q4) deprived \[[@B12-ijerph-17-05171]\]; and (ii) clinical information: All chronic disease diagnoses present at the date of infection and registered in primary care EHRs, all drugs dispensed during the month prior to infection in community and hospital pharmacies, presence of multimorbidity (i.e., the coexistence of two or more chronic conditions) and polypharmacy (i.e., the dispensation of five or more drugs), Anticholinergic Drug Scale (ADS) score \[[@B13-ijerph-17-05171]\] based on an updated version \[[@B14-ijerph-17-05171]\], and flu vaccination. During the follow-up period, we analyzed all-cause mortality. Hospitalizations and Intensive Care Unit admissions were not analyzed due to potential biases influenced by the healthcare system´s organization, amongst others.

Primary care diagnoses were initially coded using the International Classification of Primary Care, First Edition (ICPC--1). These codes were mapped to ICD-9-CM using a mapping system developed to codify temporary disability \[[@B15-ijerph-17-05171]\]. Diagnoses were subsequently sorted into 226 clinically relevant categories using the Clinical Classifications Software (CCS) for ICD-9-CM \[[@B16-ijerph-17-05171]\]. Diagnoses were classified as chronic or not chronic using the Chronic Condition Indicator software tool \[[@B17-ijerph-17-05171]\], with a total of 153 conditions categorized as chronic. Some of the diagnostic labels were renamed to facilitate their clinical interpretation. Chronic conditions were defined as those present during the last 12 months at least, and meeting one or both of the following criteria: (i) Entails limitations on self-care, independent living, and social interactions; (ii) requires of ongoing interventions using medical products, services, and special equipment. We analyzed all drugs using their Anatomical-Therapeutic-Chemical (ATC) classification system code at the third level (i.e., pharmacological subgroup). The ADS score was rated from level 0 (absence of known anticholinergic properties) to level 3 (markedly anticholinergic), as previously described \[[@B13-ijerph-17-05171],[@B14-ijerph-17-05171]\].

Patient data was obtained from the Aragon Health System linking, at a patient level and in a pseudo-anonymized form, the information contained in the users' database, primary care EHRs, primary care and hospital pharmaceutical billing records, and an *ad hoc* registry developed for monitoring the evolution of the COVID-19 disease pandemic in the region of Aragon.

2.3. Statistical Analysis {#sec2dot3-ijerph-17-05171}
-------------------------

We described the socio-demographic and clinical characteristics of all patients from the cohort (alive and deceased at the end of follow-up) as means accompanied by their respective standard deviations or as absolute and relative frequencies and proportions, by sex. Differences in means between alive and deceased men and women were analyzed using age-adjusted logistic regression analysis.

We performed logistic regression models to analyze the association between the presence of each chronic comorbidity and drug studied at baseline and the likelihood of mortality during the follow-up period, by sex. We used this technique instead of Cox regression since we had the date of registry but not the exact date of infection and/or of confirmatory test for all patients. We calculated age-adjusted odds ratios (ORs) accompanied by their respective 95% confidence intervals (CI). For this analysis, only chronic diseases and medications with at least 10 cases in deceased men and/or women were considered.

Finally, we performed a multivariate logistic regression analysis to identify which of the studied variables were significantly associated with higher mortality when studied in combination. In doing so, we included as potential explanatory variables all socio-demographic characteristics, chronic diseases and medications that showed significant association at baseline. Multivariate analysis was performed using a stepwise method with an exit *p*-value for analyzed variables of 0.05. We calculated the pseudo R squared statistics to estimate the proportion of the variation in mortality that was explained by the variables included in each model for men and women. Statistical analyses were conducted using Stata software (Version 12.0, StataCorp LLC, College Station, TX, USA), and statistical significance was set at *p* \< 0.05.

3. Results {#sec3-ijerph-17-05171}
==========

A total of 4412 individuals (58.8% women, mean age of 67.7 (standard deviation, s.d., 20.7) years) were included in the study ([Table 1](#ijerph-17-05171-t001){ref-type="table"}). Of them, 771 (47.2% women, mean age of 84.2 (s.d. 10.0) years) died during the follow-up period. The crude overall mortality rate during the studied period was 3.84 deaths per 100,000 persons per day. Three in four deceased patients were older than 80 years, compared to one in four in those alive. Men died at an earlier age than women (81.5 vs. 87.2 years). The mean numbers of chronic diseases (5.22 vs. 3.03; 6.66 vs. 3.67) and dispensed medications (5.41 vs. 3.00; 5.57 vs. 2.75) were higher in deceased men and women compared to their alive counterparts. Deceased individuals also showed a higher burden of medications with anticholinergic activity, especially women. Although the proportion of influenza-vaccinated individuals was higher in deceased compared to alive men (64.1% vs. 36.3%) and women (68.4% vs. 31.9%), these differences were not significant after controlling for age.

The most prevalent chronic conditions in the individuals of the cohort who died during the follow-up period were hypertension (49.4%), obesity and other nutritional, endocrine and metabolic disorders (28.7%), cataract (28.0%), diabetes (27.5%), and urinary incontinence (25.3%) in men, and hypertension (62.6%), urinary incontinence (50.5%), obesity and other nutritional, endocrine and metabolic disorders (37.9%), mood disorders (36.3%), and osteoarthritis (33.2%) in women ([Table 2](#ijerph-17-05171-t002){ref-type="table"}). These figures were slightly different from those observed in the entire population (see [Supplementary Table S1](#app1-ijerph-17-05171){ref-type="app"}). In men, nine conditions with at least 10 cases amongst deceased individuals were significantly associated with an increased likelihood of death, including (OR (95% CI)) epilepsy (2.56 (1.09--5.99)), inflammatory conditions of genital organs (2.56 (1.15--5.70)), and congestive heart failure (2.15 (1.30--3.54)), among others. Rheumatoid arthritis was also highly associated (5.15 (1.13--23.5)), but only five cases were observed (see [Supplementary Table S1](#app1-ijerph-17-05171){ref-type="app"}). In women, acute myocardial infarction (2.98 (1.25--7.11)), coagulation and hemorrhagic disorders (1.85 (1.15--2.97)), and degenerative nervous system conditions (1.56 (1.05--2.33)) could be highlighted amongst the eight conditions significantly associated with higher mortality. Diabetes (1.65 (1.23--2.21); 1.40 (1.02--1.91)) and chronic ulcer of the skin (2.24 (1.26--3.96); 2.04 (1.35--3.10)) were the only two conditions associated with higher mortality in both sexes.

Some of the most frequently dispensed drugs among individuals who died of both sexes were (men vs. women) drugs for peptic ulcer and gastro-esophageal reflux disease (GORD) (49.6% vs. 58.5%), antithrombotic agents (36.9% vs. 39.0%), other analgesics and antipyretics (31.0% vs. 37.4%), high-ceiling diuretics (24.6% vs. 34.6%), and antidepressants (20.4% vs. 38.7%), among others ([Table 3](#ijerph-17-05171-t003){ref-type="table"}).

The dispensation of 12 drugs in men and 9 drugs in women was associated with an increased likelihood of death during the study period. Out of all of them (OR (95% CI)), drugs for peptic ulcer and GORD (1.45 (1.13--1.86); 1.32 (1.02--1.71)), high-ceiling diuretics (1.79 (1.30--2.49); 1.71 (1.29--2.27)), antipsychotics (1.71 (1.18--2.48); 1.96 (1.41--2.73)), and potassium-sparing agents (2.52 (1.27--4.97); 2.86 (1.50--5.44)) were associated with higher risk of mortality in both men and women, respectively. Women treated with other beta-lactam antibacterials, antigout preparations, and antiepileptics presented 2.17, 2.06, and 1.94 times greater mortality risk than those not receiving these medications, respectively. Men treated with corticosteroids, vasodilators for cardiac diseases, and immunosuppressants showed 3.83, 3.15, and 2.49 times higher risk of death. Plain angiotensin-converting enzyme (ACE) inhibitors were not associated with a higher risk of death in men; however, patients in treatment with medications of ACE inhibitors in combination with other active ingredients were less likely to die (0.46 (0.23--0.93)). [Supplementary Table S2](#app1-ijerph-17-05171){ref-type="app"} displays the complete list of drugs analyzed in the study population.

The models developed to assess mortality risk revealed that age was the most influencing factor, being the risk of death between 10 and 40 times higher in men and women above 80 years of age compared with their younger 45--64-year-old counterparts ([Table 4](#ijerph-17-05171-t004){ref-type="table"}). Three diseases and six drugs in men, and three diseases and five drugs in women, remained significant in the models. In men, the likelihood of mortality was 2.04, 1.48, and 1.46 times higher when chronic ulcer of skin, cataract, and diabetes were present, respectively. In women, acute myocardial infarction, chronic ulcer of the skin and urinary incontinence were associated with 3.42, 1.65, and 1.35 times higher mortality. Corticosteroids, vasodilators, immunosuppressants, and antipsychotics were amongst the medications associated the most with an increased likelihood of mortality. The models explained 22.8% and 25.9% of the variance of mortality in men and women, respectively.

4. Discussion {#sec4-ijerph-17-05171}
=============

In this study, we described the main socio-demographic and baseline clinical characteristics of the first 771 deceased individuals with laboratory-confirmed SARS-CoV-2 infection in Aragon, Spain. We analyzed which factors were associated with an increased likelihood of mortality in order to identify potential profiles of men and women to whom prevention and control strategies should be directed during the present and possible future outbreaks of the COVID-19 disease. Our findings suggest that women and men probably share similar but not identical mortality risk factors, and that the focus should be set on older individuals with cardiovascular comorbidity and under treatment with high anticholinergic activity medications, like antipsychotics.

Advanced age is associated with a higher risk of mortality in COVID-19 patients \[[@B11-ijerph-17-05171],[@B18-ijerph-17-05171]\], which concurs with our findings (more markedly in women). We believe that the higher mortality rates reported in our study, especially among 80-year-old patients and over, could be partially explained by the severity of their clinical status (laboratory testing for COVID-19 infection was initially implemented only in patients at high risk of adverse outcomes), and the large follow-up period (up to ten weeks and at least one month from cohort entry) which allowed for a higher number of definite outcomes to occur. A recent study in 244 hospitalized COVID-19 patients aged 60 and over, with definite outcomes (discharged or deceased), reported 121 deaths (mortality rate of approximately 50%), identifying older age as one of the most important risk factors \[[@B19-ijerph-17-05171]\]. In Spain, the pandemic hit hardest in residential care homes for the elderly, at least during the first weeks of the crisis when less was known about the disease´s transmissibility and pathophysiology. This could explain, in part, the older age of infected patients in our study when compared to those of other regions. Individuals living in residential care homes are amongst the most susceptible to poorer health outcomes from COVID-19, mainly due to the higher number of underlying chronic conditions, immunosenescence, and the potential for rapid transmissibility from asymptomatic and pre-symptomatic patients \[[@B20-ijerph-17-05171],[@B21-ijerph-17-05171],[@B22-ijerph-17-05171]\]. Although the infection was more prevalent in women, we found that COVID-19 mortality was more common in men. In female adults, innate and adaptive immunity is generally stronger than in men, and males are more susceptible to infectious diseases \[[@B23-ijerph-17-05171]\]. A closer look at the deceased population in our study reveals that men were younger than women, with a lower mean number of comorbidities and medication profile with lower anticholinergic activity. A higher mean number of medications appears to be associated with poorer outcomes, especially in drugs with anticholinergic activity.

During seasonal influenza outbreaks, the reported incidence of acute cardiovascular events in elders traditionally grows, and emergency-visits for influenza-like disease have been associated with cardiovascular morbidity and mortality \[[@B24-ijerph-17-05171]\]. Previous studies reported that some patients with COVID-19 develop acute cardiac injury and that this comorbidity may result in a poorer prognosis \[[@B9-ijerph-17-05171],[@B25-ijerph-17-05171]\]. It has also been suggested that patients with underlying cardiovascular conditions might also have an increased risk of adverse outcomes \[[@B26-ijerph-17-05171],[@B27-ijerph-17-05171]\]. Our results show that chronic cardiovascular comorbidity in COVID-19 patients is associated with an increased likelihood of mortality. More precisely, male COVID-19 patients with non-hypertensive congestive heart failure are more likely to die than men without this condition. In female COVID-19 patients, we observe similar results for clinical history of acute myocardial infarction or cardiac dysrhythmias. These findings underline the need to understand how SARS-CoV-2 interacts with cardiovascular comorbidities and medications. Regarding the recent controversy over a possible adverse effect of seasonal flu shot on COVID-19 prognosis, we must highlight that no association between influenza vaccination and risk of mortality was found in our study.

Viral respiratory infections could result in the activation of pathways leading to vascular complications \[[@B24-ijerph-17-05171]\]. Various mechanisms could be contributing to cardiac injury by SARS-CoV-2, including, amongst others, direct viral infection of myocardial cells mediated by angiotensin-converting enzyme 2 (ACE2) receptors \[[@B25-ijerph-17-05171],[@B26-ijerph-17-05171],[@B27-ijerph-17-05171]\]. Activation of coagulation and inflammatory pathways could lead to vascular complications, theoretically both in the form of newly presented acute cardiovascular diseases or the deterioration of underlying chronic conditions. Various authors have recommended caution when prescribing ACE inhibitors or angiotensin-receptor blockers (ARBs) in COVID-19 patients with cardiovascular comorbidity, as this medication can increase ACE2 levels, which could potentially lead to a more severe health outcomes \[[@B28-ijerph-17-05171],[@B29-ijerph-17-05171]\]. However, in our study, we did not observe any association of plain ACE inhibitors or ARBs with mortality. This concurs with other authors, who did not find evidence of an increased risk of adverse outcomes in patients treated with ACE2 and ARBs in their studies \[[@B30-ijerph-17-05171]\]; thus, we believe that more research is needed on this aspect. Our findings underscore the importance of studying the role of ACE2 receptors in the pathophysiology of COVID-19 and of conducting longitudinal population-based epidemiological studies in order to design and validate proper preventive strategies for patients at high risk of adverse outcomes.

Multimorbidity and polypharmacy are very common among the elderly, making it challenging to identify and interpret all the possible interactions among diseases and/or drugs, especially in the presence of an emerging disease such as this one. An interesting finding in our study was that the association of specific pharmacological subgroups with a higher likelihood of mortality does not necessarily constitute a therapeutic indication for chronic diseases that were also identified as potential risk factors. This observation should be interpreted with caution, as there are many epidemiological, clinical, and pathophysiological factors that could contribute to this finding. Possible drug-related side effects and adverse reactions, and drug--drug or drug--disease interactions, could result in a substantially higher risk of poorer prognosis, particularly in multimorbid patients. Our findings may provide useful information for future studies on this aspect. An interesting observation was the higher likelihood of mortality in patients who were in treatment with high anticholinergic activity medications. Potential adverse consequences of such treatments in the elderly include cognitive and functional decline, cardiovascular complications, and other adverse effects that could lead to institutionalization or other serious outcomes \[[@B31-ijerph-17-05171],[@B32-ijerph-17-05171],[@B33-ijerph-17-05171]\].

By analyzing all statistically significant associations with an increased likelihood of mortality, we identified different models for men and women. Although these models might describe patients with different clinical profiles, a common and constant characteristic is the presence of diseases that could originate/cause vascular complications, or of medications prescribed for such conditions. Nonetheless, we must highlight that these models explained up to 23% and 26% of the variance of mortality in men and women, respectively. This means that approximately 75% of the mortality would be explained by other factors probably related to genetics, other clinical variables, or the management of the patient. Furthermore, statistical associations do not necessarily translate into the existence of causal relationships, and these findings should be interpreted with caution. Future large-scale population studies based on real-world data in different European settings are encouraged to provide the necessary evidence for the development of early identification strategies for patients at higher risk of adverse outcomes.

The main strength of this study lies in the fact that we analyzed all the individuals of the reference population with a laboratory-confirmed infection by COVID-19 who died during the study period. Baseline comorbidity was individually and exhaustively studied by analyzing a list of 153 chronic conditions, and not only the most common or severe ones. The medication burden was also exhaustively analyzed, however, we only focused on medications dispensed during the month prior to the infection, and we might have missed some of the patients' treatments. Another limitation lies in the unavailability of certain variables that would have been of interest for the aim of our study, such as socio-economic variables, genetics, laboratory tests, and inpatient treatments, amongst others.

5. Conclusions {#sec5-ijerph-17-05171}
==============

Our findings suggest that the comorbidity and medication burden present at infection with SARS-CoV-2 could partially affect the outcome of the COVID-19 disease, and that women and men probably share similar but not identical risk factors. Advanced age seems to be the most influencing factor, followed by the presence of various underlying conditions and medications, particularly those related to the cardiovascular system. Nonetheless, much of the mortality seems to be explained by other factors probably related to patients´ clinical management, genetics, and other clinical variables. More research is needed in this field, in different populations and clinical settings, to provide the necessary evidence for the development of early identification strategies for patients at higher risk of adverse outcomes.

The authors sincerely thank all professionals from Dirección General de Asistencia Sanitaria, Dirección General de Salud Pública, and Servicio Aragonés de Salud (SALUD), from Departamento de Salud del Gobierno de Aragón, for their essential collaboration to advance this research line in the midst of such challenging times. This research was funded by Gobierno de Aragón (Grant numbers B01_20R and PI20/226) and the European Regional Development Fund "Construyendo Europa desde Aragón".

The following are available online at <https://www.mdpi.com/1660-4601/17/14/5171/s1>, Table S1: Prevalence of chronic diseases at cohort entry of all the individuals of the COVID-19 Aragon cohort and of those died during the follow-up period, and association with mortality, by sex; Table S2: Prevalence of drugs dispensed during the month prior to cohort entry of all the individuals of the COVID-19 Aragon cohort and of those died during the follow-up period, and association with mortality, by sex.
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###### 

Socio-demographic and clinical characteristics at cohort entry of the individuals with laboratory-confirmed infection by COVID-19 in Aragón, Spain, March to May 2020 (*n* = 4412), by sex.

  Characteristics                             Alive ^a^ (*n* = 3641)   Dead (*n* = 771)   *p* Value ^b^                                                  
  ------------------------------------------- ------------------------ ------------------ --------------- ------ ------ ------ ------ ------ ----------- -----------
  **Age**, years                                                                                                                                         
  0--14                                       6                        0.42               0               0      0      0      0      0      \-          \-
  15--44                                      205                      14.5               516             23.1   1      0.25   0      0      0.019       \-
  45--64                                      540                      38.2               844             37.9   29     7.13   7      1.92   Reference   Reference
  65--79                                      352                      24.9               318             14.3   121    29.7   51     14.0   \<0.001     \<0.001
  ≥80                                         309                      21.9               551             24.7   256    62.9   306    84.1   \<0.001     \<0.001
  Mean (mean, sd ^c^)                         63.3                     18.1               60.8            20.2   81.5   10.7   87.2   8.20   \<0.001     \<0.001
  **Non-native** ^d^                          163                      11.5               299             13.4   8      1.97   7      1.92   0.369       0.649
  **Rural area** ^e^                          510                      36.1               768             34.5   168    41.3   161    44.2   0.121       0.473
  **Deprivation index** ^f^                                                                                                                              
  Q1                                          474                      33.6               743             33.3   130    31.9   142    39.0   Reference   Reference
  Q2                                          339                      24                 513             23.0   96     23.6   78     21.4   0.156       0.657
  Q3                                          275                      19.5               423             19.0   87     21.4   70     19.2   0.729       0.078
  Q4                                          324                      22.9               550             24.7   94     23.1   74     20.3   0.458       0.849
  **Flu vaccination**, yes                    512                      36.3               710             31.9   261    64.1   249    68.4   0.110       0.126
  **No. of chronic diseases**^g^ (mean, sd)   3.03                     3.35               3.67            3.65   5.22   4.02   6.66   4.14   0.012       0.003
  **Multimorbidity** ^h^                      793                      56.2               1410            63.3   307    75.4   311    85.4   0.398       0.022
  **No. of drugs**^i^ (mean, sd)              3.00                     3.14               2.75            3.11   5.41   3.73   5.57   3.42   \<0.001     0.006
  **Polypharmacy** ^j^                        402                      28.5               568             25.5   242    59.5   217    59.6   \<0.001     0.125
  **ADS score** ^k^                                                                                                                                      
  0                                           1106                     78.3               1680            75.4   234    57.5   168    46.2   Reference   Reference
  1                                           152                      10.8               270             12.1   76     18.7   85     23.4   0.088       0.044
  2                                           79                       5.59               128             5.74   47     11.5   60     16.5   0.091       0.003
  ≥3                                          75                       5.31               151             6.77   50     12.3   51     14.0   0.010       0.070

^a^ Alive or dead at the end of the follow-up period; ^b^ *p*-value of the comparison between alive and dead individuals by sex, using age-adjusted logistic regression analysis; ^c^ standard deviation; ^d^ Born out of Spain; ^e^ Based on the type of administrative health area (urban, if 80% or more of the population of the area is concentrated in one of the municipalities, or rural for the rest); ^f^ Calculated at aggregated level per administrative health area and divided into quartiles from less (Q1) to more (Q4) deprived; ^g^ Primary care diagnoses from a list of 153 chronic conditions, using the Clinical Classification System and the Chronic Condition Indicator; ^h^ Defined as the presence of two or more chronic diseases; ^i^ Dispensed during the month prior to cohort entry, using the Anatomical-Therapeutic-Chemical classification system at the third level (i.e., pharmacological subgroup); ^j^ Defined as the dispensation of five or more drugs; ^k^ Anticholinergic Drug Scale score.
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###### 

Prevalence of chronic diseases at cohort entry of individuals that died during the follow-up period, and association with all-cause mortality, by sex.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chronic Conditions                                             Men\                 95% CI ^a^   Women\                   95% CI                                
                                                                 (*n* = 407)                       (*n* = 364)                                                    
  -------------------------------------------------------------- ------------- ------ ------------ ------------- ---------- -------- ------ ---------- ---------- ----------
  Hypertension                                                   201           49.4   0.96         0.75          1.23       228      62.6   1.20       0.92       1.56

  **Urinary incontinence**                                       103           25.3   1.33         0.97          1.83       184      50.5   **1.50**   **1.16**   **1.94**

  Obesity and other nutritional, endocrine, metabolic dis. ^d^   117           28.7   1.02         0.78          1.34       138      37.9   1.26       0.97       1.63

  **Cataract**                                                   114           28.0   **1.62**     **1.20**      **2.18**   99       27.2   1.19       0.89       1.59

  **Mood disorders**                                             70            17.2   1.38         0.98          1.95       132      36.3   **1.46**   **1.12**   **1.91**

  Osteoarthritis                                                 74            18.2   0.93         0.67          1.29       121      33.2   1.00       0.77       1.31

  **Diabetes Mellitus**                                          112           27.5   **1.65**     **1.23**      **2.21**   80       22.0   **1.40**   **1.02**   **1.91**

  Delirium, dementia                                             60            14.7   1.04         0.72          1.49       101      27.7   1.20       0.90       1.61

  Dis. of lipid metabolism                                       70            17.2   1.22         0.88          1.70       61       16.8   0.92       0.66       1.28

  Anxiety dis.                                                   38            9.34   0.80         0.53          1.21       83       22.8   1.21       0.90       1.64

  Chronic renal failure                                          55            13.5   1.32         0.89          1.94       61       16.8   1.24       0.87       1.76

  **Cardiac dysrhythmias**                                       58            14.3   1.01         0.70          1.46       58       15.9   **1.47**   **1.02**   **2.12**

  Osteoporosis                                                   9             2.21   1.16         0.48          2.82       95       26.1   1.27       0.95       1.70

  Other ear/sense dis.                                           54            13.3   0.85         0.59          1.22       53       14.6   0.90       0.63       1.28

  Spondylosis                                                    45            11.1   1.27         0.84          1.92       54       14.8   1.10       0.77       1.57

  Hyperplasia of prostate                                        97            23.8   1.15         0.86          1.56       0        0      \-         \-         \-

  **Congestive heart failure**                                   41            10.1   **2.15**     **1.30**      **3.54**   40       11.0   1.40       0.91       2.15

  **Chronic ulcer of skin**                                      30            7.37   **2.24**     **1.26**      **3.96**   50       13.7   **2.04**   **1.35**   **3.10**

  Thyroid dis.                                                   26            6.39   1.18         0.70          1.97       53       14.6   0.82       0.58       1.16

  Glaucoma                                                       39            9.58   0.69         0.46          1.05       41       11.3   1.05       0.70       1.57

  **Hereditary/degenerative nervous system conditions**          23            5.65   1.43         0.79          2.60       49       13.5   **1.56**   **1.05**   **2.33**

  **Blindness and vision defects**                               48            11.8   **1.70**     **1.12**      **2.57**   19       5.22   0.78       0.46       1.35

  **Coagulation/hemorrhagic dis.**                               29            7.13   0.84         0.52          1.36       35       9.62   **1.85**   **1.15**   **2.97**

  Headache, including migraine                                   20            4.91   0.64         0.38          1.09       43       11.8   0.94       0.64       1.38

  **Acute cerebrovascular dis.**                                 34            8.35   **1.83**     **1.09**      **3.07**   29       7.97   1.26       0.77       2.06

  Transient cerebral ischemia                                    30            7.37   1.60         0.93          2.73       26       7.14   0.86       0.53       1.41

  Neoplasms                                                      31            7.62   1.22         0.75          1.98       18       4.95   1.41       0.77       2.58

  COPD ^e^ and bronchiectasis                                    38            9.34   0.99         0.64          1.52       10       2.75   1.17       0.54       2.55

  Upper respiratory disease                                      23            5.65   1.29         0.75          2.21       19       5.22   1.04       0.60       1.81

  Coronary atherosclerosis                                       24            5.90   1.05         0.62          1.81       17       4.67   1.07       0.59       1.97

  Diverticulosis/diverticulitis                                  18            4.42   1.25         0.67          2.35       22       6.04   1.25       0.72       2.16

  Gout                                                           30            7.37   0.85         0.54          1.35       10       2.75   1.57       0.68       3.61

  **Acute myocardial infarction**                                22            5.41   1.53         0.85          2.73       13       3.57   **2.98**   **1.25**   **7.11**

  Miscellaneous mental health dis.                               14            3.44   0.64         0.34          1.19       19       5.22   1.38       0.77       2.46

  Other nervous system dis.                                      16            3.93   0.87         0.46          1.62       15       4.12   0.79       0.43       1.44

  Acquired foot deformities                                      5             1.23   0.91         0.30          2.74       24       6.59   0.82       0.50       1.34

  Developmental dis.                                             11            2.70   1.32         0.60          2.92       16       4.40   1.22       0.65       2.27

  Parkinson's disease                                            13            3.19   1.63         0.73          3.67       13       3.57   2.10       0.96       4.60

  Asthma                                                         6             1.47   0.45         0.18          1.11       19       5.22   0.68       0.40       1.17

  Prolapse of genital organs                                     0             0      \-           \-            \-         24       6.59   1.53       0.89       2.61

  Other non-traumatic joint dis.                                 10            2.46   0.90         0.40          2.03       15       4.12   0.89       0.48       1.66

  Retinal detachments, vascular occlusion, retinopathy           12            2.95   1.89         0.84          4.25       13       3.57   1.15       0.58       2.29

  Residual codes; unclassified                                   18            4.42   1.44         0.78          2.66       5        1.37   1.84       0.58       5.84

  Menopausal dis.                                                0             0      \-           \-            \-         20       5.49   0.97       0.57       1.66

  Other gastrointestinal dis.                                    11            2.70   1.66         0.71          3.88       11       3.02   1.04       0.50       2.14

  Allergic reactions                                             14            3.44   2.02         0.93          4.39       8        2.20   0.72       0.32       1.64

  Other inflammatory condition skin                              15            3.69   1.74         0.86          3.53       7        1.92   0.75       0.31       1.79

  Esophageal dis.                                                9             2.21   0.80         0.37          1.73       11       3.02   0.85       0.42       1.72

  Other endocrine dis.                                           9             2.21   1.23         0.50          3.05       11       3.02   1.92       0.84       4.38

  **Epilepsy, convulsions**                                      12            2.95   **2.56**     **1.09**      **5.99**   8        2.20   0.96       0.41       2.25

  Adjustment dis.                                                6             1.47   0.72         0.27          1.92       13       3.57   0.98       0.50       1.92

  Peripheral, visceral atherosclerosis                           16            3.93   1.79         0.86          3.73       2        0.55   0.96       0.18       5.15

  Menstrual dis.                                                 0             0      \-           \-            \-         14       3.85   1.31       0.68       2.53

  **Inflammatory conditions of male genital organs**             13            3.19   **2.56**     **1.15**      **5.70**   0        0      \-         \-         \-

  Other bone disease and musculoskeletal deformities             1             0.25   0.38         0.04          3.40       10       2.75   1.47       0.65       3.31

  Other male genital dis.                                        10            2.46   1.41         0.65          3.06       0        0      \-         \-         \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Confidence interval; ^b^ Primary care diagnoses from a list of 153 chronic conditions, using the Clinical Classification System (CCS) and the Chronic Condition Indicator. Diseases are listed in order of descending overall prevalence; only those with at least 10 cases in men and/or women are presented. The complete list of diseases is presented in [Supplementary Table S1](#app1-ijerph-17-05171){ref-type="app"}; ^c^ Odds ratio; the OR of mortality for each basal chronic disease was estimated using logistic regression models. The ORs were adjusted by age, included in the model as a categorical variable. Conditions with statistically significant ORs in men and/or women are highlighted in bold. All the individuals of the cohort were followed for at least 30 days after cohort entry; ^d^ Disorders; ^e^ Chronic obstructive pulmonary disease.
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###### 

Prevalence of medications dispensed during the month prior to cohort entry of individuals that died during the follow-up period, and association with all-cause mortality, by sex.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medications                                                              Men\                 95% CI ^a^   Women\                   95% CI                                
                                                                           (*n* = 407)                       (*n* = 364)                                                    
  ------------------------------------------------------------------------ ------------- ------ ------------ ------------- ---------- -------- ------ ---------- ---------- ----------
  **Drugs for peptic ulcer, GORD ^d^ (A02B)**                              202           49.6   **1.45**     **1.13**      **1.86**   213      58.5   **1.32**   **1.02**   **1.71**

  **Antithrombotic agents (B01A)**                                         150           36.9   1.25         0.96          1.63       142      39.0   **1.51**   **1.16**   **1.97**

  Other analgesics and antipyretics (N02B)                                 126           31.0   1.04         0.80          1.36       136      37.4   0.93       0.72       1.21

  **High-ceiling diuretics** **(C03C)**                                    100           24.6   **1.79**     **1.30**      **2.49**   126      34.6   **1.71**   **1.29**   **2.27**

  **Antidepressants (N06A)**                                               83            20.4   1.30         0.94          1.79       141      38.7   **1.33**   **1.02**   **1.73**

  Lipid modifying agents, plain (C10A)                                     93            22.9   0.93         0.69          1.24       70       19.2   0.83       0.60       1.13

  **Beta blocking agents (C07A)**                                          85            20.9   **1.53**     **1.11**      **2.11**   68       18.7   1.28       0.92       1.79

  **Antipsychotics (N05A)**                                                70            17.2   **1.71**     **1.18**      **2.48**   82       22.5   **1.96**   **1.41**   **2.73**

  **Anxiolytics (N05B)**                                                   57            14.0   **1.52**     **1.05**      **2.22**   89       24.5   1.32       0.98       1.78

  Blood glucose lowering drugs (A10B)                                      73            17.9   1.14         0.82          1.58       48       13.2   1.28       0.88       1.88

  Drugs for prostatic hypertrophy (G04C)                                   108           26.5   0.96         0.72          1.28       0        0      \-         \-         \-

  Opioids (N02A)                                                           42            10.3   1.13         0.75          1.71       62       17.0   1.30       0.92       1.83

  **Antiepileptics (N03A)**                                                37            9.09   1.00         0.65          1.55       52       14.3   **1.94**   **1.31**   **2.88**

  ARBs ^e^, plain (C09C)                                                   45            11.1   1.16         0.78          1.74       42       11.5   0.99       0.67       1.46

  ARBs, comb. ^f^ (C09D)                                                   49            12.0   1.00         0.69          1.46       32       8.79   0.68       0.44       1.03

  ACE ^g^ inhibitors, plain (C09A)                                         40            9.83   0.90         0.60          1.36       38       10.4   1.14       0.74       1.73

  Iron preparations (B03A)                                                 35            8.60   1.44         0.88          2.35       38       10.4   1.06       0.70       1.62

  **Vitamin B12 and folic acid (B03B)**                                    45            11.1   **1.88**     **1.20**      **2.97**   28       7.69   1.16       0.71       1.88

  Adrenergics, inhalants (R03A)                                            45            11.1   1.35         0.90          2.02       24       6.59   0.98       0.60       1.62

  Selective calcium channel blockers with mainly vascular effects (C08C)   39            9.58   1.10         0.72          1.69       27       7.42   0.82       0.51       1.31

  Hypnotics and sedatives (N05C)                                           30            7.37   1.04         0.64          1.69       36       9.89   0.92       0.60       1.39

  Antiglaucoma preparations (S01E)                                         33            8.11   1.02         0.64          1.61       25       6.87   1.07       0.65       1.76

  **Antigout preparations (M04A)**                                         35            8.60   1.29         0.82          2.04       17       4.67   **2.06**   **1.05**   **4.04**

  Anti-dementia drugs (N06D)                                               18            4.42   0.73         0.40          1.32       33       9.07   0.92       0.60       1.42

  Macrolides, lincosamides (J01F)                                          26            6.39   0.84         0.51          1.36       23       6.32   1.19       0.71       2.01

  **Other drugs for obstructive airway diseases, inhalants (R03B)**        33            8.11   **1.83**     **1.10**      **3.05**   16       4.40   0.96       0.52       1.76

  B-lactam antibacterials, penicillins (J01C)                              22            5.41   0.84         0.49          1.42       24       6.59   1.62       0.94       2.79

  Quinolone antibacterials (J01M)                                          31            7.62   1.55         0.94          2.56       15       4.12   1.37       0.70       2.66

  **Potassium-sparing agents (C03D)**                                      23            5.65   **2.52**     **1.27**      **4.97**   23       6.32   **2.86**   **1.50**   **5.44**

  Corticosteroids systemic use, plain (H02A)                               23            5.65   1.44         0.82          2.54       21       5.77   1.13       0.65       1.94

  **Insulins and analogues (A10A)**                                        21            5.16   **2.33**     **1.21**      **4.48**   16       4.40   1.40       0.73       2.68

  **Vasodilators for cardiac diseases (C01D)**                             24            5.90   **3.15**     **1.55**      **6.41**   12       3.30   1.15       0.55       2.40

  Calcium (A12A)                                                           12            2.95   1.69         0.73          3.88       23       6.32   0.70       0.43       1.15

  Other systemic drugs for obstructive airway diseases (R03D)              20            4.91   1.18         0.66          2.11       10       2.75   0.78       0.37       1.62

  Vitamin A and D (A11C)                                                   7             1.72   0.90         0.35          2.30       21       5.77   1.73       0.97       3.10

  **Other beta-lactam antibacterials (J01D)**                              15            3.69   2.02         0.95          4.30       13       3.57   **2.17**   **1.00**   **4.71**

  Anti-inflammatory/ antirheumatic products, non-steroids (M01A)           13            3.19   0.58         0.31          1.10       13       3.57   0.70       0.37       1.32

  *ACE inhibitors, comb. (C09B)*                                           11            2.70   *0.46*       *0.23*        *0.93*     15       4.12   1.00       0.53       1.87

  Other antibacterials (J01X)                                              8             1.97   0.80         0.34          1.91       18       4.95   1.17       0.64       2.13

  Antihistamines for systemic use (R06A)                                   15            3.69   1.46         0.74          2.88       10       2.75   1.54       0.70       3.40

  Dopaminergic agents (N04B)                                               17            4.18   1.15         0.60          2.21       8        2.20   1.17       0.48       2.81

  Urologicals (G04B)                                                       17            4.18   1.34         0.69          2.62       7        1.92   0.80       0.34       1.92

  Psychostimulants, agents used for ADHD ^h^ and nootropics (N06B)         14            3.44   2.01         0.89          4.54       9        2.47   1.24       0.54       2.89

  Thyroid preparations (H03B)                                              8             1.97   1.22         0.48          3.09       14       3.85   0.98       0.52       1.86

  Drugs affecting bone structure and mineralization (M05B)                 7             1.72   2.42         0.71          8.22       14       3.85   0.82       0.43       1.56

  Selective calcium channel blockers with direct cardiac effects (C08D)    11            2.70   1.09         0.50          2.37       10       2.75   1.46       0.65       3.31

  **Immunosuppressants (L04A)**                                            11            2.70   **2.49**     **1.08**      **5.76**   3        0.82   0.89       0.24       3.27

  **Corticosteroids, plain (D07A)**                                        11            2.70   **3.83**     **1.43**      **10.3**   3        0.82   0.61       0.16       2.25

  Lipid modifying agents, comb. (C10B)                                     10            2.46   0.95         0.44          2.02       2        0.55   0.29       0.07       1.27
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Confidence interval; ^b^ Drugs were coded using the Anatomical-Therapeutic-Chemical (ATC) classification system at the third level (i.e., pharmacological subgroup). Drugs are listed in descending order of overall frequency of dispensation; only those with at least 10 cases in men and/or women are presented. The complete list of drugs is presented in [Supplementary Table S2](#app1-ijerph-17-05171){ref-type="app"}; ^c^ Odds ratio; the OR of mortality for each dispensed drug was estimated using logistic regression models. The ORs were adjusted by age, included in the model as a categorical variable. Drugs with statistically significant ORs in men and/or women are highlighted in bold (OR \> 1) or in italics (OR \< 1). All the individuals of the cohort were followed for at least 30 days after cohort entry; ^d^ Gastro-esophageal reflux disease; ^e^ Angiotensin II receptor blockers; ^f^ Combinations; ^g^ Angiotensin-converting enzyme; ^h^ Attention-deficit hyperactivity disorder.
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###### 

Models of likelihood of mortality according to baseline demographic and clinical variables of the individuals with laboratory-confirmed infection by COVID-19, by sex.

  Variables ^a^                           OR ^b^      95% CI ^c^ Lower Limit   95% CI Upper Limit   *p*-Value
  --------------------------------------- ----------- ------------------------ -------------------- -----------
  **Men** (*n* = 407)                                                                               
  *Age (years)*                                                                                     
  0--14                                   \-                                                        
  15--44                                  0.10        0.01                     0.73                 0.024
  45--64                                  Reference                                                 
  65--79                                  5.18        3.35                     8.03                 \<0.001
  ≥80                                     10.4        6.75                     16.1                 \<0.001
  *Chronic diseases*                                                                                
  Chronic ulcer of skin                   2.04        1.14                     3.65                 0.017
  Cataract                                1.48        1.08                     2.01                 0.014
  Diabetes Mellitus                       1.46        1.08                     1.98                 0.014
  *Drugs*                                                                                           
  Corticosteroids, single drugs           3.32        1.25                     8.80                 0.016
  Vasodilators used in cardiac diseases   2.77        1.33                     5.75                 0.006
  Immunosuppressive agents                2.54        1.08                     5.98                 0.033
  Potassium-sparing agents                2.45        1.23                     4.88                 0.011
  Antipsychotics                          1.66        1.13                     2.43                 0.009
  Vitamin B12 and folic acid              1.69        1.05                     2.70                 0.029
  **Women** (*n* = 364)                                                                             
  *Age (years)*                                                                                     
  0--14                                   \-                                                        
  15--44                                  \-                                                        
  45--64                                  Reference                                                 
  65--79                                  15.7        6.99                     35.0                 0.000
  ≥80                                     40.7        18.8                     88.3                 0.000
  *Chronic diseases*                                                                                
  Acute myocardial infarction             3.42        1.41                     8.32                 0.007
  Chronic ulcer of skin                   1.65        1.07                     2.54                 0.024
  Urinary incontinence                    1.35        1.04                     1.77                 0.027
  *Drugs*                                                                                           
  Peripheral vasodilators                 5.49        1.29                     23.3                 0.021
  Potassium-sparing agents                2.17        1.10                     4.29                 0.026
  Antipsychotics                          1.81        1.29                     2.53                 0.001
  Antiepileptics                          1.63        1.08                     2.45                 0.019
  High-ceiling diuretics                  1.41        1.04                     1.90                 0.028

^a^ Demographic (age) and clinical (chronic diseases and drugs) variables that remained significant of all the analyzed ones in each of the models after performing multivariate stepwise logistic regression with an exit *p*-value for variables of 0.05; ^b^ Odds ratio; ^c^ Confidence interval.
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